Literature DB >> 26996665

The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

I Roth1,2, H Campbell3, C Rubio3, C Vennin4, M Wilson1, A Wiles1, G Williams1, A Woolley1, P Timpson4, M V Berridge5, N Fleming1, M Baird1,2, A W Braithwaite1,2,3.   

Abstract

A number of naturally occurring isoforms of the tumour suppressor protein p53 have been discovered, which appear to have differing roles in tumour prevention or promotion. We are investigating the tumour-promoting activities of the Δ133p53 isoform using our mouse model of Δ133p53 (Δ122p53). Here, we report that tumours from Δ122p53 homozygous mice show evidence of invasion and metastasis and that Δ122p53 promotes migration though a 3-dimensional collagen matrix. We also show that Δ122p53 and Δ133p53 promote cell migration in scratch wound and Transwell assays, similar to the 'gain-of-function' phenotypes seen with mutant p53. Using the well-defined B16 mouse melanoma metastatic model, we show that Δ122p53 leads to faster generation of lung metastases. The increased migratory phenotypes are dependent on secreted factors, including the cytokine interleukin-6 and the chemokine CCL2. We propose that Δ122p53 (and Δ133p53) acts in a similar manner to 'gain-of-function' mutant p53 proteins to promote migration, invasion and metastasis, which may contribute to poor survival in patients with Δ133p53-expressing tumours.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26996665     DOI: 10.1038/onc.2016.45

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities.

Authors:  Fukun Guo; Yuan Gao; Lei Wang; Yi Zheng
Journal:  J Biol Chem       Date:  2003-02-10       Impact factor: 5.157

2.  Inflammation and p53: A Tale of Two Stresses.

Authors:  Andrei V Gudkov; Katerina V Gurova; Elena A Komarova
Journal:  Genes Cancer       Date:  2011-04

3.  Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma.

Authors:  Nichapavee Nutthasirikul; Temduang Limpaiboon; Chanvit Leelayuwat; Siriporn Patrakitkomjorn; Patcharee Jearanaikoon
Journal:  Int J Oncol       Date:  2013-02-08       Impact factor: 5.650

4.  Mutant p53 drives invasion by promoting integrin recycling.

Authors:  Patricia A J Muller; Patrick T Caswell; Brendan Doyle; Marcin P Iwanicki; Ee H Tan; Saadia Karim; Natalia Lukashchuk; David A Gillespie; Robert L Ludwig; Pauline Gosselin; Anne Cromer; Joan S Brugge; Owen J Sansom; Jim C Norman; Karen H Vousden
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

5.  p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.

Authors:  Serif Senturk; Zhan Yao; Matthew Camiolo; Brendon Stiles; Trushar Rathod; Alice M Walsh; Alice Nemajerova; Matthew J Lazzara; Nasser K Altorki; Adrian Krainer; Ute M Moll; Scott W Lowe; Luca Cartegni; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-29       Impact factor: 11.205

6.  Expression of p53 isoforms in squamous cell carcinoma of the head and neck.

Authors:  Linda Boldrup; Jean-Christophe Bourdon; Philip J Coates; Björn Sjöström; Karin Nylander
Journal:  Eur J Cancer       Date:  2007-01-09       Impact factor: 9.162

7.  Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.

Authors:  Jean-Philippe Coppé; Christopher K Patil; Francis Rodier; Yu Sun; Denise P Muñoz; Joshua Goldstein; Peter S Nelson; Pierre-Yves Desprez; Judith Campisi
Journal:  PLoS Biol       Date:  2008-12-02       Impact factor: 8.029

8.  B cells and professional APCs recruit regulatory T cells via CCL4.

Authors:  R S Bystry; V Aluvihare; K A Welch; M Kallikourdis; A G Betz
Journal:  Nat Immunol       Date:  2001-12       Impact factor: 25.606

9.  Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53.

Authors:  Hind Hafsi; Daniela Santos-Silva; Stéphanie Courtois-Cox; Pierre Hainaut
Journal:  BMC Cancer       Date:  2013-03-20       Impact factor: 4.430

10.  Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties.

Authors:  G Davatelis; P Tekamp-Olson; S D Wolpe; K Hermsen; C Luedke; C Gallegos; D Coit; J Merryweather; A Cerami
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  18 in total

1.  The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.

Authors:  Madison Miller; Nitin Shirole; Ruxiao Tian; Debjani Pal; Raffaella Sordella
Journal:  J Cancer Biol Res       Date:  2016-12-23

2.  SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.

Authors:  ShuYan Liu; Xiao Li; ZhaoMin Lin; Le Su; Shan Yan; BaoXiang Zhao; JunYing Miao
Journal:  Cancer Lett       Date:  2017-12-13       Impact factor: 8.679

Review 3.  A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Authors:  Marina Kazantseva; Sunali Mehta; Ramona A Eiholzer; Noelyn Hung; Anna Wiles; Tania L Slatter; Antony W Braithwaite
Journal:  Mamm Genome       Date:  2018-07-10       Impact factor: 2.957

4.  Conformational stability and dynamics of the cancer-associated isoform Δ133p53β are modulated by p53 peptides and p53-specific DNA.

Authors:  Jiangtao Lei; Ruxi Qi; Yegen Tang; Wenning Wang; Guanghong Wei; Ruth Nussinov; Buyong Ma
Journal:  FASEB J       Date:  2018-12-12       Impact factor: 5.834

5.  TP53 drives invasion through expression of its Δ133p53β variant.

Authors:  Gilles Gadea; Nikola Arsic; Kenneth Fernandes; Alexandra Diot; Sébastien M Joruiz; Samer Abdallah; Valerie Meuray; Stéphanie Vinot; Christelle Anguille; Judit Remenyi; Marie P Khoury; Philip R Quinlan; Colin A Purdie; Lee B Jordan; Frances V Fuller-Pace; Marion de Toledo; Maïlys Cren; Alastair M Thompson; Jean-Christophe Bourdon; Pierre Roux
Journal:  Elife       Date:  2016-09-15       Impact factor: 8.140

6.  Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology.

Authors:  James R W Conway; Claire Vennin; Aurélie S Cazet; David Herrmann; Kendelle J Murphy; Sean C Warren; Lena Wullkopf; Alice Boulghourjian; Anaiis Zaratzian; Andrew M Da Silva; Marina Pajic; Jennifer P Morton; Thomas R Cox; Paul Timpson
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

7.  SRSF1 promotes vascular smooth muscle cell proliferation through a Δ133p53/EGR1/KLF5 pathway.

Authors:  Ning Xie; Min Chen; Rilei Dai; Yan Zhang; Hanqing Zhao; Zhiming Song; Lufeng Zhang; Zhenyan Li; Yuanqing Feng; Hua Gao; Li Wang; Ting Zhang; Rui-Ping Xiao; Jianxin Wu; Chun-Mei Cao
Journal:  Nat Commun       Date:  2017-08-11       Impact factor: 14.919

8.  p53 targets TSPAN8 to prevent invasion in melanoma cells.

Authors:  G Agaësse; L Barbollat-Boutrand; M El Kharbili; O Berthier-Vergnes; I Masse
Journal:  Oncogenesis       Date:  2017-04-03       Impact factor: 7.485

9.  A functional interplay between Δ133p53 and ΔNp63 in promoting glycolytic metabolism to fuel cancer cell proliferation.

Authors:  Lu Gong; Xiao Pan; Chuan-Bian Lim; Anna de Polo; John B Little; Zhi-Min Yuan
Journal:  Oncogene       Date:  2018-01-26       Impact factor: 9.867

10.  ∆133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling.

Authors:  Hamish Campbell; Nicholas Fleming; Imogen Roth; Sunali Mehta; Anna Wiles; Gail Williams; Claire Vennin; Nikola Arsic; Ashleigh Parkin; Marina Pajic; Fran Munro; Les McNoe; Michael Black; John McCall; Tania L Slatter; Paul Timpson; Roger Reddel; Pierre Roux; Cristin Print; Margaret A Baird; Antony W Braithwaite
Journal:  Nat Commun       Date:  2018-01-17       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.